Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Clinical-stage biotech, small molecule drugs for inflammatory/metabolic diseases: gout, NASH.
Atom Bioscience & Pharmaceutical is a clinical-stage biotechnology company developing small molecule therapeutics for inflammatory and metabolic diseases, headquartered in Suzhou, China, with additional operations in the United States. The enterprise focuses on treatments for chronic gout, hyperuricemia, and nonalcoholic steatohepatitis, advancing its lead oral URAT1 inhibitor candidate, ABP-671, through global Phase 2b/3 clinical trials. Operating without current product revenue, the firm recently entered an exclusive commercialization agreement with China Medical System Holdings to distribute this primary asset. The venture-backed business has secured approximately $160 million in total funding to date, including an $83 million Series D financing round to support ongoing global pivotal trials. This capital was raised from a syndicate of institutional investors featuring HongShan, Oriza Holdings, Fortune Venture Capital, and Kaitai Capital. Atom Bioscience & Pharmaceutical was founded in 2012 by Dr. William Shi.
Atom Bioscience & Pharmaceutical has raised $127.1M across 2 funding rounds.
Atom Bioscience & Pharmaceutical has raised $127.1M in total across 2 funding rounds.
Atom Bioscience & Pharmaceutical has raised $127.1M across 2 funding rounds. Most recently, it raised $82.1M Series D in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 16, 2023 | $82.1M Series D | Kaitai Capital | Fortune Capital, Huajin Investment | Announced |
| Jan 5, 2022 | $45M Series C | Yuhang Teng, Huang PU | Efung Capital, Hongshan Capital Group (Sequoia Capital China), Kaitai Capital, Livzon Pharmaceutical Group, Unifortune Investment Holdings Group | Announced |
Atom Bioscience & Pharmaceutical has raised $127.1M in total across 2 funding rounds.
Atom Bioscience & Pharmaceutical's investors include Kaitai Capital, Fortune Capital, Huajin Investment, Yuhang Teng, Huang Pu, Efung Capital, Hongshan Capital Group (Sequoia Capital China), Livzon Pharmaceutical Group, Unifortune Investment Holdings Group.